Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.

Barton, Simon; Munday, P E; Kinghorn, G R; Meijden, W I van der; Stolz, Eveline Dischkaln; Notowicz, A.; Rashid, Sumara; Schuller, JC; Essex-Cater, A; Kuijpers, M H

doi:10.1136/sti.62.4.247

Cited by 15 publications

(8 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These moderate effects on the clinical course of the disease are similar to those previously described in clinical trials of topical foscarnet for the treatment of recurrent cutaneous herpes in immuncompetent patients (Barton et al, 1986;Spruance et al, 1986). Examination of the virus titres in the ears on day 7 post-infection showed, however, that antiviral treatments significantly reduced the virus titre compared to placebo.…”

Section: Discussionsupporting

confidence: 60%

Combinations of Antiviral and Anti-Inflammatory Preparations for the Topical Treatment of Herpes Simplex Virus Assessed using a Murine Zosteriform Infection Model

Awan

Harmenberg

Flink³

et al. 1998

Antivir Chem Chemother

View full text Add to dashboard Cite

Recently we have reported a zosteriform murine infection model which employs the adoptive transfer of immune cells (All) to recipient infected mice to produce a disease that mimics human recurrent herpes simplex virus (HSV) disease. Mice were infected with HSV-1 by scarification at the lateroventral line of the neck; 2 days later, the mice received immune cells from HSV-1-infected syngeneic mice. Although virus was cleared more quickly from the target tissues of virus replication in recipient mice, ATI resulted in a heightened inflammatory response and delayed healing. This model was used to test the effects of topical formulations containing foscarnet and/or the antiinflammatory agent, hydrocortisone. Virus clearance and clinical signs, including ear thickness and zosteriform spread of lesions, were

show abstract

Section: Discussionsupporting

confidence: 60%

Combinations of Antiviral and Anti-Inflammatory Preparations for the Topical Treatment of Herpes Simplex Virus Assessed using a Murine Zosteriform Infection Model

Awan

Harmenberg

Flink³

et al. 1998

Antivir Chem Chemother

View full text Add to dashboard Cite

show abstract

“…In a single-centre clinical study on recurrent genital herpes only a limited, but statistically significant, effect of topical 0.3% foscarnet cream on time to healing was observed in men (Wallin et al, 1985). However, in two multi-centre trials on recurrent genital herpes no statistically significant improvements in time to healing or loss of symptoms were observed with foscarnet (Barton et al, 1986;Sacks et al, 1987). Compilation of several studies showed that patients who initiated treatment in the prevesicular stage had a slightly reduced number of days with sores (Astra Alab AB, unpublished data).…”

Section: Introductionmentioning

confidence: 80%

Limited Efficacy of Inhibitors of Herpes Simplex Virus DNA Synthesis in Murine Models of Recrudescent Disease

Kristofferson

Ericson

Sohl‐Åkerlund

et al. 1988

Journal of General Virology

View full text Add to dashboard Cite

The herpesvirus DNA polymerase inhibitor foscarnet, applied topically, and the anti-herpesvirus guanosine analogue buciclovir, given orally, decreased virus replication and disease development in primary skin infections of mice caused by herpes simplex virus type 1 (HSV-1). If the same tissues were infected via sensory nerves, following zosteriform spread of the virus the same treatments showed strongly decreased efficacy, or were inefficacious, when started before development of clinical signs in the infected tissues. These results were obtained in murine models of zosteriform spread of HSV-1 to the ear (following inoculation of the ventral side of the neck) or to the lower flank (following inoculation of the upper flank). In these models the immune system played a dominant role in virus clearance. The topically applied foscarnet could not prevent disease development in these models of recrudescent disease even when applied before the virus was detected in the skin, but a decrease in virus titre was obtained. Orally administered buciclovir lost efficacy when administered at the time of virus entry into the skin, i.e. 1 or 2 days before development of clinical signs. In the flank model, measuring lesion development, orally administered acyclovir also had a strongly decreased efficacy, when compared with its effect during infections in which lesion development did not involve translocation of virus through nerves. In the presence of developing immunity the inhibitors could not accelerate the clearance of virus from infected tissues. Furthermore, all treatments (topical foscarnet and oral buciclovir or acyclovir) were without effect on disease development when treatment was initiated on appearance of the first clinical signs of disease. As disease development following zosteriform spread of HSV resembles that in recurrent herpes in humans, and as the limited efficacy of the inhibitors observed resembles the poor results obtained with inhibitors of herpesvirus DNA synthesis in clinical studies on the treatment of symptomatic recurrent herpes, we suggest the use of animal models of zosteriform spread for pre-clinical evaluation of new antiherpes drugs.

show abstract

“…Conversely, no significant improvements in time to healing or loss of symptoms were observed for recurrent genital herpes in two other clinical trials [25,26]. Patients who received treatment in the prevesicular stage had a slightly reduced number of days with lesions [27].…”

Section: Introductionmentioning

confidence: 92%

Evaluation of Some Pyrazoloquinolines as Inhibitors of Herpes Simplex Virus Type 1 Replication

Bekhit

El-Sayed

Aboul‐Enein

et al. 2005

Archiv der Pharmazie

View full text Add to dashboard Cite

Three structurally related aminopyrazoloquinoline derivatives were evaluated for their antiviral activity against Herpes Simplex virus type 1. These compounds were examined for their in vitro antiviral activity by two different bioassays, namely; crystal violet staining and tetrazolium dye (MTS) measurement. The antiviral role of these compounds was confirmed by enumerating the infectious particles with plaque assay. The acute toxicity values of the biologically active compounds were determined prior to their screening as antiviral agents.

show abstract

Topical treatment of recurrent genital herpes simplex virus infections with trisodium phosphonoformate (foscarnet): double blind, placebo controlled, multicentre study.

Cited by 15 publications

References 12 publications

Combinations of Antiviral and Anti-Inflammatory Preparations for the Topical Treatment of Herpes Simplex Virus Assessed using a Murine Zosteriform Infection Model

Combinations of Antiviral and Anti-Inflammatory Preparations for the Topical Treatment of Herpes Simplex Virus Assessed using a Murine Zosteriform Infection Model

Limited Efficacy of Inhibitors of Herpes Simplex Virus DNA Synthesis in Murine Models of Recrudescent Disease

Evaluation of Some Pyrazoloquinolines as Inhibitors of Herpes Simplex Virus Type 1 Replication

Contact Info

Product

Resources

About